Compare Quest Diagnostics Inc (DGX) vs RLX Technology Inc (RLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs RLX Technology Inc — how do they compare? Quest Diagnostics Inc trades at $230.97 (market cap $25.48B), while RLX Technology Inc trades at $1.73 (market cap $2.10B). The key difference: Quest Diagnostics Inc is far larger — about 12.1× RLX Technology Inc's market cap, and RLX Technology Inc pays the higher dividend (5.81%). Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and RLX Technology Inc for 35 Days on average.
| DGX | RLX | |
|---|---|---|
Market Cap | $25.48B | $2.10B |
Volume | 941,866 | 1,079,706 |
Sector | Health | Consumer Staples |
52-Week High | $247.45 | $2.57 |
52-Week Low | $173.49 | $1.68 |
Typical Hold Time | 56 Days | 35 Days |
Enterprise Value | $31.23B | $832.26M |
Dividend Yield | 1.49% | 5.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.81, up 1.68% with strong year-to-date performance driven by organic growth and advanced diagnostics adoption. The company has consistently beaten earnings expectations in recent quarters with Q2 2026 EPS of $3.12 exceeding estimates. Technical indicators show a bearish bias while fundamentals remain solid with 9.19% net margin and 14.35% ROE. Recent developments include a partnership with Apple Health app and positive clinical study results.
DGX presents a mixed outlook with strong fundamental performance offset by technical weakness and regulatory headwinds. The 38% upside to consensus price target of $250 offers potential, but Medicare reimbursement cuts and bearish technical signals warrant caution. Growth in consumer testing and strategic partnerships provide catalysts, though execution risks and debt levels require monitoring.
RLX trades at $1.72, near its 52-week low, with a bearish technical signal and mixed earnings history, missing EPS estimates in recent quarters. The company reported $3.62B revenue and $921.87M net income for 2025, with profitability margins showing strength but international expansion driving growth amid margin compression. Recent news highlights share price weakness and strategic acquisitions in Europe.
The outlook remains cautious due to near-term earnings misses and bearish technicals, but discounted valuation and international growth offer potential upside. Key risks include regulatory pressures and competitive threats in the e-vapor market, while analyst sentiment is neutral with a single hold rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About RLX Technology Inc
RLX Technology Inc. is a leading e-vapor company in China, focusing on the research, development, and sale of e-vapor products. The company primarily operates under the RELX brand, offering a range of closed-system e-vapor products designed to deliver a high-quality user experience. RLX's business model is centered on product innovation, strong brand building, and a vast distribution network across China.
Read more on RLX →
